



Date: 17 August, 2026

To,
BSE Ltd.,
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai – 400 001

Scrip Code: 539730

Sub.: Intimation regarding permission to trade and admission of Equity Shares to dealings on the National Stock Exchange of India Limited.

Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), read with NSE Circular Ref. No. 1355/2026 dated August 14, 2026 regarding securities permitted to trade and admitted to dealings on the Exchange.

Dear Sir/ Madam,

Pursuant to Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Equity Shares of the Company have been **permitted to trade and admitted to dealings on the National Stock Exchange of India Limited (NSE) with effect from August 17, 2026**, pursuant to **NSE Circular Ref. No. 1355/2026 dated August 14, 2026**, issued under Regulation 3.1.1 of the National Stock Exchange (Capital Market) Trading Regulations, Part A.

The Equity Shares of the Company are permitted to trade on the NSE with effect from August 17, 2026 under the following details:

Particulars	Details
Name of the Company	Fredun Pharmaceuticals Limited
ISIN	INE194R01017
NSE Symbol	FREDUN
Date of commencement of trading on NSE	August 17, 2026
Face Value	Rs. 10/-
Nature of securities	Equity



FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No: L24239MH1987PLC043662



The Company is already listed on BSE Limited and, pursuant to the aforesaid NSE circular, its Equity Shares are now permitted to trade on NSE.

We request you to take the above information on record.

Yours truly,

For Fredun Pharmaceuticals Limited

Fredun Nariman Medhora

Managing Director

DIN: 01745348

